Shift Seen to Newer Agents to Treat Psoriasis
Biologics and small molecule inhibitors increasingly used for treatment of newly diagnosed psoriasis.
Psoriasis
Tapinarof Cream Looks Promising for Plaque Psoriasis
The double-blind, vehicle-controlled studies (PSOARING 1 and PSOARING 2) assessed the efficacy and safety of tapinarof in 1025 patients aged 18 to 75 years with plaque psoriasis.
Stelara Approved for Pediatric Plaque Psoriasis
The approval of ustekinumab in pediatric patients was based on data from a phase 3 open-label, single-arm study (CADMUS Junior).
Bimekizumab Bests Secukinumab in Plaque Psoriasis Trial
Positive results were announced from a phase 3b study comparing bimekizumab (UCB) to secukinumab for the treatment of moderate to severe plaque psoriasis.
Wynzora Cream Approved for Plaque Psoriasis
Wynzora is a combination of calcipotriene, a synthetic vitamin D3 analogue, and betamethasone dipropionate, a corticosteroid, which utilizes the Company’s proprietary PAD Technology platform enabling stability of both agents in an aqueous formulation.
Mirikizumab Tops Secukinumab in Plaque Psoriasis Trial
Among patients with moderate to severe plaque psoriasis, treatment with mirikizumab (Lilly) was found to be noninferior to secukinumab (Cosentyx; Novartis).
Roflumilast Cream Promising for Chronic Plaque Psoriasis
More patients in roflumilast groups have IGA score indicating status of clear or almost clear at week 6.
Biosimilar Hulio Gets FDA Approval
The Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp; Mylan), a biosimilar to Humira® (adalimumab; AbbVie).
Imsidolimab Gets Orphan Drug Designation for Generalized Pustular Psoriasis
Generalized pustular psoriasis is a rare systemic inflammatory disease characterized by inflamed skin and small pustules.
Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study
New data from a head-to-head study comparing risankizumab-rzaa to secukinumab in patients with moderate to severe plaque psoriasis were recently presented online at the American Academy of Dermatology virtual annual meeting.
